Nanotechnology @ MaxInno

Welcome to Nano@MaxInno

Nano is disruptive technology. An ongoing industrial revolution - or perhaps an ongoing scientific one? There are already so many different sources about how this new disruption happens - and it's hard to follow. I'm interested in how science becomes commercial(ized). I'm interested in how nano changes medine and environmental protection, how nano and photonics seems to change scientific barriers: a new scientific paradigm appearing? Cross-disciplinary? Or did the "classical" scientist just not see it? The answer lies in what makes it to market.

Nano@MaxInno is my selection of articles, which I find particularly well suited to document the "revolution". In between you'll find my own articles, marked as such (not much yet, but they will come). I invite you to become guest editors. Just write to me and explain why you wish to become one. Try [email protected] and I'll grant you a co-editor's rights.

Purpose? Reflections, insights into nano, praise, concerns - about who, how, why commercialize science.

If you want to know more about who I am go visit my Home Page at icnet.dk

Industry Analysts Predict Revenues from Products Incorporating Nanotechnology to Reach Close to $3 Trillion US Within 10 Years

Industry Analysts Predict Revenues from Products Incorporating Nanotechnology to Reach Close to $3 Trillion US Within 10 Years: "In their study, Global Industry Analysts, Inc. (GIA) notes the success of nanotechnology commercialization in the healthcare and electronics section will bolster revenues for all products incorporating nanoscale technologies over the next decade. The GIA’s report also looks at government spending in nanotechnology research and development--from 2006 to 2010, Japan will be the world leader in this category, providing about $6 Billion US for nanotech R&D. The US is not too far behind with a projected $5.6 Billion US dedicated to nanotech R&D, followed by the European Union at about $4.6 Billion US for the same period."

(Via NSTI Nano World News™.)

Technology Review: Testing Drugs with Stem Cells

Technology Review: Testing Drugs with Stem Cells: " My.TechnologyReview.com: > Login > Register   Home Infotech Biotech Nanotech Energy Biztech Magazine Newsletters Events [1] Thursday, December 13, 2007 Testing Drugs with Stem Cells Researchers are using human embryonic stem cells to determine the toxicity of potential pharmaceuticals. By Jennifer Chu Print E-mail Audio » New! Share » Toxic targets: Researchers at the University of Wisconsin-Madison used embryonic stem cells to detect the toxic effects of valproate, an anti-epileptic drug that has been linked to cases of autism and spina bifida. Credit: Gabriela Cezar Lab Related Articles: •  Liver Models Go to Market 11/29/2007 •  A Better Toxicity Test 03/01/2006 •  Stem Cells without the Embryos 11/20/2007 Other readers liked: •  Building Better Implants 09/28/2007 •  Nonstick Chewing Gum 10/05/2007 •  A New Nanogenerator 10/22/2007 •  Mission to Mars: A True Story 10/15/2007 •  Intel Completes Photonics Trifecta 10/10/2007 Testing the toxicity of pharmaceutical ca"

(Via .)

AlphaGalileo.Org - the Internet-based news centre for European science, engineering and technology.

AlphaGalileo.Org - the Internet-based news centre for European science, engineering and technology.: "About Us Site Help Contact Us Log-on      The world's leading resource for European research news    View All    Science    Arts    Technology    Health    Society    Humanities       You are in: View all » Press Releases » Release  Register as a journalist for full access Register as a contributor to post your news AlphaGalileo Home About Us Register Press Releases Calendar Books Library Links Broadcast media Expert service Address book Search Advanced search   Press Releases Printable version For further information, please contact: Please register to view contact details 12 December 2007 Light and sound – the way forward for better medical imaging Detection and treatment of tumours, diseased blood vessels and other soft-tissue conditions could be significantly improved, thanks to an innovative imaging system being developed that uses both light and sound. The system uses extremely short pulses of low-energy laser light to stimulate the emission "

(Via .)

Innovation Centre with Nanotechnology Commercialization Focus Officially Opens

Innovation Centre with Nanotechnology Commercialization Focus Officially Opens: " Home Databases News Resources Nanowerk Nanotechnology Introduction Career Center Printer-friendly E-mail this article Posted: September 28, 2007 Innovation Centre with Nanotechnology Commercialization Focus Officially Opens (Nanowerk News) The NINT Innovation Centre, a part of the National Institute for Nanotechnology (NINT) of the National Research Council of Canada, was officially opened today. The Centre rents space to start-up and existing companies or to industrial collaborators that will benefit from the close proximity to the high concentration of nanotechnology expertise at NINT and across the University of Alberta campus. Its objective is to help Canadian companies exploit the potential of nanotechnology and to foster the growth of an Edmonton-area cluster of companies that utilize nanotechnology. The Centre occupies the fourth floor of the NINT building and consists of 15 rental units of combined office and laboratory space. Current tenants include five companies "

(Via .)

News: Alnylam Stock Soars on $1B Pact with Roche. Genetic Engineering News - Biotechnology from Bench to Business

News: Alnylam Stock Soars on $1B Pact with Roche. Genetic Engineering News - Biotechnology from Bench to Business: " NEWS GEN News Highlights News from the Wires News by Subject Subscribe to RSS Subscribe to E-Alerts BIOBUSINESS Overview News StockWatch Articles Corporate Profiles DRUG DISCOVERY Overview News Articles Tutorials Conferences/Meetings OMICS Overview News Articles Tutorials Conferences/Meetings BIOPROCESSING Overview News Articles Tutorials Conferences/Meetings TRANSLATIONAL MEDICINE Overview News Articles Conferences/Meetings CURRENT ISSUE Table of Contents New Products Best of the Web Subscribe Past Issues Link to Advertisers INTERACTIVE GENcasts Blogs StockWatch CURRENT ISSUE AD LINK Past Issues HOME Podcasts Blogs New Products Best of the Web GEN Updates Oligonucleotides Next-Generation Sequencing Transfection Jobs Find a Job Post a Job Classified Mart Announcements Marketplace Real Estate Conferences/Meetings Biotech Companies Resources Editorial Meet the Editors Editorial Calendar Editorial Guidelines Subscribe To GEN To E-Alerts To RSS Advertise 2007 Media Kit 2007"

(Via .)

Developing nanotechnology noses to 'smell' cancer

Developing nanotechnology noses to 'smell' cancer: " Home Database News Resources Nanowerk Nanotechnology Introduction Career Center Printer-friendly E-mail this article Subscribe Posted: July 2, 2007 Developing nanotechnology noses to 'smell' cancer (Nanowerk Spotlight) Biomarkers are of increasing importance in modern medicine for the purpose of early detection and diagnosis of a disease, for instance cancer. Biomarkers are mostly protein molecules that can be measured in blood, other body fluids, and tissues to assess the presence or state of a disease. For example, the presence of an antibody may indicate an infection or an antigen, such as PSA, might indicate the presence of prostate-specific cancer cells. Although protein-based approaches to early detection and diagnosis of cancer have a clear advantage over other, more invasive, methods, protein detection is a challenging problem owing to the structural diversity and complexity of the target analytes. State-of-the-art detection methods have limited application due to "

(Via .)

The end for the UK's leading nanotechnology company?

The "Nano Bubble to burst" ???? Dejá vu?

The end for the UK's leading nanotechnology company?: " or The end for Britain's leading nanotechnology company? In our news on April 9 we reported that the future of Oxonica, Britain's was in doubt ('Future of UK's leading nanotechnology company is in doubt'). Yesterday, the Financial Times reported that shares in Oxonica were suspended after the nanotechnology company lost its biggest customer. Last month Oxonica warned that trials of its Envirox diesel catalyst with Petrol Ofisi, Turkey's biggest diesel supplier, were proving inconclusive. Petrol Ofisi has now formally notified the company of the termination from July 10 of the contract to supply Envirox. Source: Financial Times

(Via .)

Portugese-German research cooperation includes nanotechnology

Portugese-German research cooperation includes nanotechnology: " or Home Database News Resources Nanowerk Nanotechnology Introduction Career Center Printer-friendly E-mail this article Posted: April 26, 2007 Portugese-German research cooperation includes nanotechnology (Nanowerk News) A Portuguese-German research cooperation agreement was signed in the city of Porto last week. The Portuguese Prime Minister Jose Socrates, the Minister of Science, the German Secretary of State for Education and Research, Professor Frieder Meyer-Krahmer, senior Fraunhofer officials, industrial leaders and Portuguese academic partners all attended the event. The new collaboration will significantly expand applied research on emerging technologies, exploring mutual interests in science and technology oriented towards social well-being, economic growth and quality of life. The ultimate goal of the agreement is to establish a collaborative framework to promote continuous and systematic cooperative actions between Fraunhofer Institutes and R&D institutions in Po"

(Via .)

More on Arrowhead Research and Carbon Nanotechnologies Complete Merger

Arrowhead Research and Carbon Nanotechnologies Complete Merger: "   Arrowhead Research and Carbon Nanotechnologies Complete Merger Arrowhead Research Corporation announced today that its majority-owned subsidiary, Unidym, Inc., has closed the merger with Carbon Nanotechnologies, Inc. The combined company, which will operate under the Unidym name, has the dominant portfolio of carbon nanotube-related patents and is one of the largest manufacturers of carbon nanotubes in the world. The merger positions the company as a leader in bringing carbon nanotube-based products to market. ‘In addition to integrating the operations of the two companies, our priority over the coming months will be developing strategic partnerships and the licensing program,’ said R. Bruce Stew"

(Via .)

Nanotech Delivery Request: A Corporate Presentation from Merck Research Laboratories

Nanotech Delivery Request: A Corporate Presentation from Merck Research Laboratories: "Nanotech Delivery Request: A Corporate Presentation from Merck Research Laboratories Apr 17, 2007 Representatives from Merck will make a special presentation to researchers and scientists in universities and companies at the Nanotech 2007 conference on May 23, 2007 at the Santa Clara Convention Center in California. Merck recently acquired Sirna Therapeutics, a leader in efforts to create RNAi-based therapeutics that could significantly alter the treatment of disease. RNAi-based therapeutics selectively catalyze the destruction of the RNA transcribed from an individual gene enabling an novel approach to discovering drugs with the potential to produce highly specific, potent, and long-lasting effects. The presentation will focus on areas Merck is especially interested in developing collaboration around enabling technologies that can be applied to the targeted delivery of siRNA particles in-vivo. Examples might include self-assembling polymer nanoparticles and cellular/organ-specific targeting strategies. Merck will also discuss their interest in novel assays to follow intracellular processing and trafficking of siRNA. The presentation will be followed by a question and answer period and one-on-one meetings. To view the full program and register for the Nanotech Conference, please visit: www.nsti.org/Nanotech2007/."

(Via .)